MedTrace Logo

Study of Intra-articular Allocetra in Knee Osteoarthritis

NCT06233474 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-04-30

No results posted yet for this study

Summary

This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra compared to placebo in patients with symptomatic knee osteoarthritis.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

Allocetra

Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state

OTHER

Placebo

The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.

Sponsors & Collaborators

  • Nordic Bioscience Clinical Development (NBCD)

    collaborator UNKNOWN

  • Enlivex Therapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Lital Weinfeld-Bergman · Senior Director of Clinical Operations

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-26
Primary Completion
2026-03-15
Completion
2026-05-15

Countries

  • Denmark
  • Israel
  • Moldova

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06233474 on ClinicalTrials.gov